Heparin beyond anti-coagulation
- PMID: 34237474
- PMCID: PMC8257468
- DOI: 10.1016/j.retram.2021.103300
Heparin beyond anti-coagulation
Abstract
Heparin has served as a mainstream anticoagulant for over eight decades. Clinically heparin-derived compounds significantly contribute to prevention and treatment of thrombotic events complicated in numerous medical conditions such as venous thromboembolism, coronary artery disease and extracorporeal circulation processes. Moreover in recent years, various off-labeled efficacious potentials of heparin beyond anti-coagulation are dramatically emerging, and increasingly investigated in clinical studies. Herein this article presents a comprehensive update on the expanded applications of heparin agents, covering the pregnant clinic, respiratory inflammation, renal disease, sepsis, pancreatitis, among others. It aims to maximize the beneficial profile of a pharmaceutical product through medical re-purposing development, exemplified by heparin, to address the unmet clinical needs of severe illness including coronavirus disease 2019 (COVID-19).
Keywords: Heparin; Medical re-purpose; Non-anticoagulant efficacy.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Complement activation and coagulopathy - an ominous duo in COVID19.Expert Rev Hematol. 2021 Feb;14(2):155-173. doi: 10.1080/17474086.2021.1875813. Epub 2021 Jan 22. Expert Rev Hematol. 2021. PMID: 33480807
-
Anticoagulation for COVID-19 Patients: A Bird's-Eye View.Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211039288. doi: 10.1177/10760296211039288. Clin Appl Thromb Hemost. 2021. PMID: 34595937 Free PMC article. Review.
-
Plasma Antithrombin Values Are Significantly Decreased in Coronavirus Disease 2019 (COVID-19) Patients with Severe Illness.Semin Thromb Hemost. 2021 Jun;47(4):460-462. doi: 10.1055/s-0040-1716873. Epub 2020 Dec 30. Semin Thromb Hemost. 2021. PMID: 33378783 Review. No abstract available.
-
Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit.Int J Lab Hematol. 2021 Dec;43(6):1284-1290. doi: 10.1111/ijlh.13543. Epub 2021 Apr 14. Int J Lab Hematol. 2021. PMID: 33855802 Free PMC article.
-
Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Mar 10;22(1):202. doi: 10.1186/s13063-021-05076-0. Trials. 2021. PMID: 33691765 Free PMC article.
Cited by
-
Untoward immune effects of modern medication.J Biomed Res. 2023 Dec 18;38(1):17-23. doi: 10.7555/JBR.37.20230071. J Biomed Res. 2023. PMID: 38105750 Free PMC article.
-
The postpartum uterine ultrasonographic scale in assessment of uterine involution after cesarean section in treated thrombophilia pregnant patients at term.J Clin Lab Anal. 2022 Sep;36(9):e24645. doi: 10.1002/jcla.24645. Epub 2022 Aug 5. J Clin Lab Anal. 2022. PMID: 36082463 Free PMC article.
-
A novel risk stratification approach and molecular subgroup characterization based on coagulation related genes in colon adenocarcinoma.Cancer Cell Int. 2024 Sep 9;24(1):309. doi: 10.1186/s12935-024-03491-2. Cancer Cell Int. 2024. PMID: 39252019 Free PMC article.
-
Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment.Pharmaceuticals (Basel). 2023 Feb 10;16(2):271. doi: 10.3390/ph16020271. Pharmaceuticals (Basel). 2023. PMID: 37259415 Free PMC article. Review.
-
Application of artificial neural network in daily prediction of bleeding in ICU patients treated with anti-thrombotic therapy.BMC Med Inform Decis Mak. 2023 Aug 31;23(1):171. doi: 10.1186/s12911-023-02274-5. BMC Med Inform Decis Mak. 2023. PMID: 37653495 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical